Skip to content
drillr.ai

VERA

Vera Therapeutics, Inc.

NASDAQ · USHealthcareBiotechnology
$36.99-3.92%

Price as of Jul 20, 2026

VERA news

Vera Therapeutics, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 32,100 shares of Class A common stock and restricted stock units (RSUs) underlying 16,050 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Indu

    Globe Newswire ·

  2. Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy

    * TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA nephropathy (IgAN).(1,2) * The TRUTAKNA dose is 150 mg injected subcutaneously once weekly, self-administered via an autoinjector by patients at home.(1) * Investor webcast is scheduled for July 7 at 4:30 pm EDT. (https://www.globenewswire.com/Tracker?data=ZmSXWF7gdu1770A62V7HOdVYhZ0mujYs3NMkvJAV

    Globe Newswire ·

  3. Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference

    BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026. The management team will also participate in one-on-one investor meetings. Pre

    Globe Newswire ·

  4. Vera Therapeutics Appoints Christopher Hite to Board of Directors

    BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics’ Board of Directors. "It is a pleasure to welcome Chris to ou

    Globe Newswire ·